Introduction
Surface epithelium of the airways, intestine and reproductive tissues comprise a mucosal barrier to viral infection, and underlie the inability of viruses to express genes in these cell types in vitro and in vivo. Methods employed by the epithelium to safeguard against viral infection (e.g. downregulation of receptor molecules, blockade of entry, [1] [2] [3] [4] [5] [6] intracellular virion degradation, 7, 8 gene silencing 9, 10 ) protect cells from infection and vitiate viral activity. For example, tumor transduction by suicide genes, cytokines and other therapeutic constructs generally displays efficiencies at least 1-2 orders of magnitude below thresholds necessary to elicit 'bystander' tumor regressions. [11] [12] [13] [14] In genetic diseases such as cystic fibrosis, low levels of gene transfer (e.g. 5% of target airway cells) may be capable of correcting bioelectric abnormalities and improving prognosis, but it has not yet been possible to achieve this level of genetic correction in vivo. 15, 16 In alpha-1 antitrypsin deficiency, sickle cell anemia, phenylketonuria, metabolic storage and other diseases, inefficient transgene expression represents a primary impediment to therapeutic development. [17] [18] [19] [20] [21] Agents that confer substantial transduction efficiency at lower viral inocula (lower multiplicity of infection, MOI) could be useful in a number of clinical settings both ex vivo and in vivo.
In the present study, we screened compound libraries for activators of adenoviral gene transfer. Seven compounds were identified as strong potentiators of this process in otherwise refractory epithelial cells. Based on the hypothesis that certain features underlying epithelial resistance to adenovirus might be relevant to other vector subtypes, we tested two of the agents in protocols using lenti-, adeno-associated virus (AAV) and liposomal transduction. We describe new compound families with broad-spectum activity as gene transfer potentiators.
to adenoviral gene transfer, form polar monolayers under the growth conditions described here 22 and reproduce many features of epithelial refractoriness to adenoviral gene transfer described previously in cultured cells and murine models in vivo [22] [23] [24] [25] [26] [27] [28] [29] (see also below). Figure 1 (upper panel) depicts the general approach and assay layout. Row A of each test tray contained HeLa cells (with and without virus). Row B contained uninfected HT29 cells as a negative control. Columns 1 and 12 (C-H) contained HT29 cells infected with virus alone as a second (negative) control. All other wells were used for testing individual compound solutions in triplicate. The lower panel of Figure 1 depicts a typical result from the assay. Wells F6-H6 in the example demonstrate a potential 'hit' observed during primary screening. This compound produced a signal on the order of that observed in the positive (HeLa) control (wells A7-A12).
Seven strong activators belonging to the NCI diversity set increased luciferase activity in confluent HT29 cell monolayers ( Figure 2 , panel a). Luminescence from HeLa cells (positive control) is shown for comparison. Chemical formula for each active compound is provided in Figure 3 . NSC143491 (daunomycin 3-oxime hydrochloride), a derivative of daunorubicin (NSC82151), is a member of the anthracycline family of compounds that act as topoisomerase II inhibitors. The parent compound (daunorubicin) is clinically approved for treatment of acute myeloid leukemia and acute lymphocytic leuke- ). As shown in Figure 4c , addition of NSC675865 increased luminescence in this cellular model for CFTR activity. 32 Results with NSC675865 and a lentivirus expressing luciferase are shown in Figure 5 . Addition of the compound increased luminescence in HT29 cells in a fashion exhibiting dose dependence on both viral MOI and concentration of the potentiator. 
Discussion
Compounds that potentiate gene expression by more than one vector class are less likely to depend on a specific viral receptor molecule (e.g. CAR or heparin sulfate utilized by adenovirus and AAV-2, respectively) or other events specific to a particular virus. 1, 7, 8, 33, 34 Agents such as NSC143491 and NSC675865 augment viral transduction into both nonpolarizing and polarizing cell types, and therefore are likely to act within target cells, themselves, rather than on paracellular or junctional complexes that block access to basolateral uptake. HeLa cells, for example, lack paracellular or junctional complexes and yet exhibit gene transfer enhancement up to 1000-fold ( Figure 6 ). Thus, effects on paracellular permeability alone do not appear to account for the findings presented here. In further support of this, transepithelial resistance (a very sensitive method for determining tight junction integrity) was measured in parallel experiments. No changes in monolayer resistances were attributable to drug administration, including incubations identical to the 4-h treatment schedules that strongly augment both viral and nonviral gene transfer. Because potentiation was noted using two different transgenes (GFP, luciferase), improved stability of specific mRNA molecules are also less likely to explain these findings.
We have not observed increased apical endocytosis mediated by NSC675865 or NSC143491 (data not shown). Lentiviral vectors (unlike adenovirus and AAV) may utilize both endocytic uptake and enter the cytosol Compound discovery for viral gene transfer EJ Sorscher et al directly through the plasma membrane, 35 providing further evidence against a generic increase in a single uptake pathway by NSC675865. The findings could suggest a general mechanism enhancing foreign gene delivery to the nucleus of target cells, or alterations in the pathways that govern transgene silencing, for example. In either case, the results presented here point to generalized effects on gene transfer by functionally independent vectoring systems in the airway, intestinal and other epithelia.
Viral gene transfer of cancer chemosensitizing genes such as HSV-tk and cytosine deaminase has been limited by inadequate transduction efficiency and poor bystander killing. 12 Viral gene transfer by newer generation 'suicide' genes designed specifically for an improved bystander effect are approximately 10-fold below the thresholds necessary for eliciting tumor cures, as judged by studies of lentiviral transduced tumor cell lines. 36, 37 Similarly, use of durable expression vectors such as AAV in clinical trials of cystic fibrosis and other inherited diseases suggests gene transfer efficiencies approaching, but still below thresholds necessary for phenotypic improvement. Coadministration of compounds such as those described here could be studied for their ability to potentiate viral transduction in these preclinical settings in vivo.
Topoisomerase inhibitors (such as etoposide and camptothecin) are known to enhance AAV-mediated gene expression. 34, 38 To our knowledge, topoisomerase inhibitors have not been shown previously to augment other viral or nonviral transduction systems. One of the compounds identified in our study (NSC143491) is a daunorubicin derivative and therefore could be acting through effects on topoisomerase (at least insofar as AAV is concerned). No gene transfer-related activation has been reported previously (using either viral or nonviral methods) for any of the other six compound classes identified through the present analysis. No toxicity was conferred by these compounds following experimental exposures, as judged by commercially available cytotoxicity and cell viability assay kits (LDH release and tetrazonium incorporation, data not shown).
High throughput screening has been applied to therapeutic drug development for cystic fibrosis, cholera and secretory diarrhea, HIV, cancer and a number of other conditions. [39] [40] [41] [42] The primary findings of the current report describe a screen of 23 000 agents for activation of 
Materials and methods

Cell culture
All experiments using human cells were conducted following approval of the UAB human subjects Institutional Review Board. HT29 CL19A 22 and HeLa cell lines were cultured in DMEM with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. For drug screening, cells were seeded into 96-well plates (white walls for luciferase assay, Corning-Costar 3610, Acton, MA, USA). ) by approximately 7 days after seeding. CFBE were cultured on 6.5 mm transwell filters using DMEM/F12 with 7% FBS, and exhibit monolayer resistances of approximately. 500 O cm 2 by approximately 5 days post-seeding. Cytotoxicity of the agents was assessed using Promega Cytotox (Madison, WI, USA) and Molecular Probes (Eugene, OR, USA) Vybrant Cytoxicity assay kit reagents.
The choice of cell lines and culture conditions was determined based on (1) measurements of transepithelial resistance, (2) demonstrating ZO-1 (tight junctional) staining and other localization assays and (3) vectoral Cl À transport across monolayers (a sensitive measure that verifies junctional integrity). Many of these features have been reported previously by our laboratory and others 22, 30, 31, [43] [44] [45] [46] for these cell types.
Compounds
Four drug libraries were evaluated in this study: (1) The National Cancer Institute provided approximately 21 000 agents representing 140 000 agents as a diversity set based on common pharmacophore features (http:// dtp.nic.nih.gov/index.html). Compounds were shipped in 96-well format in DMSO at a final concentration of 1 or 10 mM; (2) The Kettering-Meyer laboratory at Southern Research Institute (Birmingham, AL, USA) reviewed their drug repository of unique, synthetic compounds, and provided B2000 drugs, which included a number of unique purine and pyrimidine nucleosides, bases and related molecules; (3) Children's Hospital of Alabama formulary prepared 318 compounds representing clinically approved drugs. Compounds were dissolved in physiologic saline solutions at 1 mM; and (4) The Department of Biology at the University of Alabama at Birmingham and the Department of Chemistry at the University of South Florida supplied 252 organic extracts from Antarctic marine invertebrates. These were prepared at a concentration of 1 mM in ethanol or DMSO, and diluted 1:100 in Opti-MEM prior to use.
Adenovirus production
Ad-Luc (E1-deleted adenovirus encoding the firefly luciferase gene) used in this study expressed the transgene under control of the CMV promoter. Adenovirus was produced by conventional methods utilizing CsCl gradient centrifugation. 47, 48 Briefly, HEK293 cells were infected with adenovirus seed stock (MOI of 10), harvested by freeze/thaw and debris removed by centrifugation. Adenoviral purification was by sequential ultracentrifugation in discontinuous followed by a continuous gradient. Purified adenovirus encoding luciferase was aliquoted in 250 ml volumes and stored at À801C. Virus titer was determined by infecting 293 cells in six-well plates with 10-fold serial dilution of viral stocks and counting plaques.
Lentiviral vector production
Lentiviral vector production as described by Trono and co-workers was based on a packaging system consisting of three vectors: pMD.G (envelope vector), pCMVDR8.91 (packaging vector encoding luciferase) and pHR'CMV W Sin (expression vector) (http://www.tronolab.unige.ch/ x-reagents.htm). 49 This packaging system is deleted in all viral auxiliary genes (vpr, vif, vpu and nef) and incorporates a transgene cassette flanked by cis-acting elements necessary for encapsidation, reverse transcription and integration. A sin (self-inactivating) component blocks transcriptional capacity of the viral long terminal repeat once transferred to target cells, and the post-transcriptional regulatory element of woodchuck hepatitis virus acts to enhance transgene expression. Following transfection of the three plasmids, lentiviral particles were collected from tissue culture supernatant and concentrated by sucrose cushion centrifugation as described. 49, 50 The resulting lentivirus expressed luciferase under the control of the CMV promoter.
AAV vector production rAAVs were generated by two plasmid transfections into 293 cells by the calcium phosphate method. 51 The vector plasmid (pAAV, Stratagene, La Jolla, CA, USA) carries a luciferase or GFP expression cassette including the CMV promoter flanked by AAV-2 inverted terminal repeats. The helper plasmid (pDG) contains both AAV-2 (rep and cap) and adenoviral genes (VA, RNA, E4, E2A). The use of pDG helper plasmid (instead of adenovirus) permits helper virus-free rAAV generation through controlled rep Compound discovery for viral gene transfer EJ Sorscher et al and cap expression. rAAV released from cell pellets was purified through iodixanol gradient centrifugation, followed by heparin column chromatography and a centricon filter concentration step (Millipore, Villerica, MA, USA). To determine infectious titer, a known volume of purified rAAV encoding GFP was used to transduce 293 cells, followed by enumeration of transgene-positive cells by in situ staining and GFP fluorescence. rAAV titers of 10 11 particles/ml, with a ratio of infectious to defective particles from 1:50 to 1:100, is typically obtained by this method.
Lipid-mediated gene transfer
HT29 cells were cultured in 24-well plates until confluent, and then transfected with a plasmid encoding luciferase under SV40 promoter control (pGL3, Promega, Madison, WI, USA). Transfection was performed using FuGene (Roche Biochemical, IN, USA) per manufacturer's protocol. Briefly, 1 mg of pGL3 was mixed with 3 mg of FuGene and added to each well containing 1 ml of Opti-MEM (Invitrogen, Carlsbad, CA, USA). Test compound (40 mM) was incubated with FuGene/DNA during transfection. The media were replaced with fresh DMEM (10% FBS) after 4 h. Luciferase activity was measured at 24 h post-transfection.
Primary screening procedure
Once HT29 cells reached confluency (4-5 days), media were removed and replaced with 50 ml test solution. The solution contained 200 mM test compound diluted in Opti-MEM (Invitrogen, Carlsbad, CA, USA). Three million plaque-forming units (PFU) Ad-Luciferase diluted in Opti-MEM in 50 ml was added to each well. The final inoculum included 100 mM test compound and Ad-Luc at MOI ¼ 10 in 100 ml. Each test solution was assayed in triplicate. The cells were then incubated at 371C for 4 h, after which virus and compounds were removed and replaced with 200 ml of culture medium. Cells were incubated for additional 48 h prior to luminescence monitoring (Promega BrightGlo luciferase reagent, Madison, WI, USA) according to manufacturer's protocol with a multiwell luminometer (Harta, Gaithersburg, MD, USA).
Primary screen analysis
The average signal from HT29 cells exposed with each compound or extract was compared to control (confluent) HT29 cells (with virus, but no compound). Conditions that produced a signal 1.5 times above control were selected for further investigation. Of approximately 23 000 agents screened, 37 met this requirement.
Confirmatory screening procedures
A total of 37 compounds were tested at least 12 additional times each to confirm potency and consistency in HT29 cells. Potentiator data are presented for all active compounds against a model of epithelium that is highly resistant to adenoviral gene expression. Drugs consistently eliciting signals 420-fold above control using adenovirus were designated 'strong activators', and included seven novel scaffolds from five chemical families. Certain compounds were also evaluated in other polarizing cell lines (Calu3, normal airway submucosal gland epithelial; CFBE) 22 and with transgenes encoded by lentivirus and AAV. For the latter study, compound and vector were added to target cells for 4 h, after which medium was replaced (no virus or potentiator). Reporter gene activity was measured 48 h later.
